Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy
European Journal of Cancer · 2026
DOI: 10.1016/j.ejca.2025.116149 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von S Dugas-Breit und 21 weiteren Autor:innen. Beteiligte Einrichtung: Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology, and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partner…. Hauptthemen laut MEDLINE: Melanoma, Quality of Life, Antibodies, Monoclonal, Humanized, Cancer Survivors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heidelberg University, Medical Faculty Heidelberg, Department of Dermatology, and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, Germ…
- Department of Dermatology, University Hospital Tuebingen, Tuebingen, Germany.
- Department of Dermatology, Uniklinikum Erlangen, Comprehensive Cancer Center Erlangen - EMN, CCC WERA, Friedrich-Alexander-Universität Erlangen-Nürnberg, Deutsches Zentrum Immuntherapie (DZI), Erlangen, Germany.
- Department of Dermatology, Johannes Wesling Medical Center Minden, Ruhr University Bochum, Minden, Germany.
- Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Germany.
- Department of Dermatology, Elbe Kliniken Stade-Buxtehude, Buxtehude, Germany.
Zitieren
APA
Dugas-Breit, S., Forschner, A., Erdmann, M., Gutzmer, R., Kähler, K. C., Holst, I., Brekner, A., Franklin, C., Sindrilaru, A., Zimmer, L., Heinzerling, L., Utikal, J., Meier, F., Bender, A., Berking, C., Garbe, C., Weichenthal, M., Schadendorf, D., Hauschild, A., …, & Hassel, J. C. (2026). Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116149
Vancouver
Dugas-Breit S, Forschner A, Erdmann M, Gutzmer R, Kähler KC, Holst I, et al. Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116149
BibTeX
@article{DugasBreit2026,
author = {Dugas-Breit, S and Forschner, A and Erdmann, M and Gutzmer, R and Kähler, K C and Holst, I and Brekner, A and Franklin, C and Sindrilaru, A and Zimmer, L and Heinzerling, L and Utikal, J and Meier, F and Bender, A and Berking, C and Garbe, C and Weichenthal, M and Schadendorf, D and Hauschild, A and Gschnell, M and Mohr, P and Hassel, J C},
title = {Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy},
journal = {European Journal of Cancer},
year = {2026},
doi = {10.1016/j.ejca.2025.116149}
}
EUVIMED